GE HealthCare Falls 13.5% After Profit Miss and Outlook Cut

businesscompany-earningsstocks 3 posts · 3 accounts

GE HealthCare shares were down 13.5% at $59.22 by 15:06 UTC after the company reported a first-quarter profit miss and cut its profit outlook, citing supply issues and higher costs. Revenue rose 7.4% to $5.1 billion, or 2.9% organically, while diluted earnings per share fell to 85 cents from $1.23 a year earlier and adjusted EPS slipped to 99 cents from $1.01.

The company said first-quarter profitability was hurt by a Pharmaceutical Diagnostics supplier issue that has since been resolved. It also said increases in memory chips, oil and freight costs during the quarter are expected to affect the rest of 2026, though it expects to offset more than half of the inflation impact through price and cost actions.

From the sources (3 posts)

@business

GE HealthCare shares sank after the company reported a profit miss and cut its outlook, citing supply issues and higher costs

@alphasenseinc

$GEHC Earnings: - Revenues of $5.1 billion, up 7.4%, including Organic revenue growth of 2.9%, driven by Pharmaceutical Diagnostics (PDx), Advanced Visualization Solutions (AVS), and Imaging, with overall strength in U.S., EMEA, and Rest o

@thetranscript_

GE HealthCare CEO: "“Profitability in the first quarter was impacted by a PDx supplier issue that has since been resolved. We saw significant increases in memory chips, oil and freight costs during the first quarter that we assume will imp

Market impact

22 small

GEHC

Why it matters: GE HealthCare's Q1 profit miss and outlook cut, driven by a resolved PDx supplier issue plus memory/oil/freight cost inflation, is a company-specific hit to its own earnings with no genuine read-through that resets med-device/imaging peers or a sector ETF.

At publish time: Headline states a 13.5% drop on a profit miss AND an outlook cut — a forced guidance cut (harder to fake than PR) is the tradable hook, but drivers cited are idiosyncratic/macro-cost, keeping it single-name.

model confidence: high

What happened next

1–2 weeks later

no follow-up

No corpus follow-up on GEHC or imaging/med-device peers; listed items are unrelated earnings names. Company-specific hit, no sector read-through, consistent with prediction.

based on follow-up coverage

Follow-up coverage

No follow-up coverage matched this story.

Atlassian Shares Jump After Revenue Beat and Higher Outlook Western Union Plans Solana Stablecoin Launch Next Month